EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning. My name is Kevi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

EyePoint Pharmaceuticals (EYPT) reported $14.03 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 33.2%. EPS of -$0.33 for the same period compares to -$0.61 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.71 million, representing a surprise of +61.00%. The company delivered an EPS surprise of +45.00%, with the consensus EPS estimate being -$0.60.While investors scrutinize revenue and earnings changes year-over-year and how they ...

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025 – – Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024 – – Announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chi ...

The market expects EyePoint Pharmaceuticals (EYPT) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the au ...

zoranmEyePoint (NASDAQ:EYPT) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901. EYP-1901 has three possible uses (Wet AMD, NPDR and DME) each of which are multi-billion dollar markets, but after rising 400%+ in less than a year, the stock isn't a home run anymore and risks remain. FinVizA quick recap, the company de ...

WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 49,000 s ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...